Curosurf.com Website Review

This information is exclusively for US healthcare professionals This information is exclusively for US healthcare professionals The benefits of CUROSURF® (poractant alfa) work together to deliver fast RDS success in conventionally treated infants1-4 The benefits of CUROSURF may help you succeed in the reduction of surfactant utilization in your NICU3,5,6,9-13 CUROSURF—the #1 used surfactant in the US and worldwide —continues to keep pace with today's clinical practice14,15 severity of respiratory disease, maturity, and presence of other complications, and thus it is necessary to individualize patient care. Meet with your Chiesi Sales Representative to learn more about CUROSURF. CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory as*essments so that oxygen and ventilatory support can be modified to respond to respiratory changes. CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants. Transient adverse reactions as*ociated with administration of CUROSURF include bradycardia, hypotension, endotracheal tu*e blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring. Pulmonary hemorrhage, a known complication of prema*ure birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial